| 2025-11-18 |
详情>>
股本变动：
变动后总股本64238.41万股
|
| 2025-11-12 |
详情>>
业绩披露：
2024年年报每股收益17.66美元,归母净利润11.33亿美元,同比去年增长-73.97%
|
| 2025-11-12 |
详情>>
业绩披露：
2022年年报每股收益11.47美元,归母净利润7.50亿美元,同比去年增长-74.64%
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益14.95美元,归母净利润9.32亿美元,同比去年增长-76.69%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益8.47美元,归母净利润5.31亿美元,同比去年增长-80.57%
|
| 2025-08-07 |
财报披露：
美东时间 2025-08-07 盘前发布财报
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益3.06美元,归母净利润1.95亿美元,同比去年增长-85.28%
|
| 2025-02-13 |
股东大会：
将于2025-03-12召开股东大会
会议内容 ▼▲
- 1.Candidates for the Board of Directors;
2.Proposed amended Remuneration Policy is attached.
|
| 2025-02-13 |
股东大会：
将于2025-03-12召开股东大会
会议内容 ▼▲
- 1.Candidates for the Board of Directors;
2.Proposed amended Remuneration Policy is attached.
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益62.09美元,归母净利润39.99亿美元,同比去年增长7.73%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益42.13美元,归母净利润27.33亿美元,同比去年增长72.65%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益20.29美元,归母净利润13.25亿美元,同比去年增长530.95%
|
| 2024-02-16 |
股东大会：
将于2024-03-13召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2023 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2023 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors:
7.1Approval of remuneration to the Board of Directors for 2024.
7.2Indemnification of members of the Board of Directors
7.3Amendment of the Articles of Association (indemnification scheme)
7.4Adoption of a Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S.
7.5Authorizations to the Board of Directors to increase the share capital of the Company and to let the Company issue convertible debt instruments.
7.6Authorization to Board of Directors to let the Company issue warrants.
|
| 2024-02-16 |
股东大会：
将于2024-03-13召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2023 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2023 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors:
7.1Approval of remuneration to the Board of Directors for 2024.
7.2Indemnification of members of the Board of Directors
7.3Amendment of the Articles of Association (indemnification scheme)
7.4Adoption of a Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S.
7.5Authorizations to the Board of Directors to increase the share capital of the Company and to let the Company issue convertible debt instruments.
7.6Authorization to Board of Directors to let the Company issue warrants.
|
| 2024-02-14 |
详情>>
业绩披露：
2023年年报每股收益66.64美元,归母净利润43.52亿美元,同比去年增长480.27%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益56.84美元,归母净利润37.12亿美元,同比去年增长-24.83%
|
| 2023-02-23 |
股东大会：
将于2023-02-23召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2022 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2022 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors
(a)Approval of remuneration to the Board of Directors for 2023.
(b)Adoption of an amendment to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (remove the cap on the fair value (calculated on the grant date) for the annual share-based instruments awarded to members of the Executive Management).
(c)Adoption of amendments to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (certain other changes).
(d)Authorization to the Board of Directors to mandate the Company to acquire treasury shares.
8.Authorization of the chair of the General Meeting.
9.Any other business.
|
| 2023-02-23 |
股东大会：
将于2023-02-23召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2022 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2022 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors
(a)Approval of remuneration to the Board of Directors for 2023.
(b)Adoption of an amendment to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (remove the cap on the fair value (calculated on the grant date) for the annual share-based instruments awarded to members of the Executive Management).
(c)Adoption of amendments to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (certain other changes).
(d)Authorization to the Board of Directors to mandate the Company to acquire treasury shares.
8.Authorization of the chair of the General Meeting.
9.Any other business.
|
| 2023-02-23 |
股东大会：
将于2023-02-23召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2022 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2022 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors
(a)Approval of remuneration to the Board of Directors for 2023.
(b)Adoption of an amendment to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (remove the cap on the fair value (calculated on the grant date) for the annual share-based instruments awarded to members of the Executive Management).
(c)Adoption of amendments to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (certain other changes).
(d)Authorization to the Board of Directors to mandate the Company to acquire treasury shares.
8.Authorization of the chair of the General Meeting.
9.Any other business.
|
| 2022-02-24 |
股东大会：
将于2022-03-29召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2021 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2021 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors:(a)Approval of remuneration to the Board of Directors for 2022.
8.Authorization of the chair of the General Meeting.
9.Any other business.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-09 |
股东大会：
将于2021-04-13召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2020 and resolution to discharge Board of Directors and Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Presentation of an advisory vote on the 2020 Compensation Report.
5.Election of members of the Board of Directors.
6.Election of auditor.
7.Proposals from the Board of Directors:
7.1.Approval of remuneration to the Board of Directors for 2021.
7.2.Adoption of an amendment to the Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (decrease of the multiplier of the base fee for the chair and deputy chair of the Board of Directors).
7.3.Adoption of amended Remuneration Policy for the Board of Directors and Executive Management of Genmab A/S (certain other changes).
7.4.Authorization to Board of Directors to mandate the Company to acquire treasury shares.
7.5.Authorizations to Board of Directors to increase the share capital of the Company by cash payment and to let the Company issue convertible debt instruments.
7.6.Authorization to Board of Directors to let the Company issue warrants.
7.7.Authorization to Board of Directors to assemble general meetings as wholly virtual general meetings.
8.Authorization of the chair of the General Meeting.
9.Any other business.
|
| 2020-03-24 |
股东大会：
将于2020-03-26召开股东大会
会议内容 ▼▲
- 1.Report by the Board of Directors on the Company’s activities during the past year.
2.Presentation and adoption of the audited Annual Report 2019 and resolution to discharge the Board of Directors and the Executive Management from liability.
3.Resolution on the distribution of profits as recorded in the adopted Annual Report.
4.Election of members of the Board of Directors.
5.Election of auditor.
6.Proposals from the Board of Directors:
6.1Adoption of the Remuneration Policy for the Board of Directors and the Executive Management of Genmab A/S.
6.2Approval of remuneration to the Board of Directors for 2020.
6.3Amendment of Article 6 of the Company’s Articles of Association regarding the provider of share registration services.
7.Authorization of the chairman of the General Meeting.
8.Any other business.
|